GermanyGermany

Finalists of the European Biotechnica Award nominated

26.08.2009

Hanover - The jury of the European Biotechnica Award has selected the three finalists for 2009: The nominees are the biopharmaceutical companies NovImmune, Switzerland, TRION Pharma GmbH, Germany, and Vivalis, France. The award recognizes the achievements of young, innovative European companies from the areas of biotechnology and the life sciences.
NovImmune develops monoclonal antibodies for the treatment of inflammatory and immune-related disorders. The company is based in Plan-les-Quates, near Geneva, Switzerland, and so far has generated seven monoclonal antibodies with the intent to treat immune-related disorders.
TRION Pharma is a biopharmaceutical company that develops trifunctional antibodies called Triomab® at its site in Munich. They are based on a platform technology for which TRION Pharma holds IP rights around the world. Triomab® antibodies simultaneously activate multiple immune defence mechanisms against cancer.
Vivalis provides the pharmaceutical industry with cell-based solutions for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. Headquartered in France, the company specialises in the field of embryonic stem cells and their practical applications in human and veterinary medicine.
The international jury of experts, consisting of eleven members and chaired by Prof. Dr. Peter Stadler, CEO of Artemis Pharmaceuticals in Cologne, will decide on the ultimate winner immediately before the award ceremony during the BIOTECHNICA opening event on 5 October. The winner will receive prize money of EUR 30,000. In addition, all finalists will receive numerous non-cash prizes. The award will be presented by opening speakers Janez Potocnik, EU Commissioner for Science and Research, Dr. Philipp Rösler; Minister of Economics, Lower Saxony; Dr. Stefan Marcinowski, Member of the Board of Executive Directors of BASF and President of the German Association of Biotechnology Industries; and Kary Mullis, winner of the Nobel Prize in Chemistry.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/finalists-of-the-european-biotechnica-award-nominated.html

Product of the week

Products

Events

All Events

Current issue

All issues